-
Pirfenidone is InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis to reduce decline in lung function.
FORBES: Magazine Article
-
InterMune announced that the FDA has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee meeting to review their New Drug Application for pirfenidone.
FORBES: Magazine Article
-
The proposed trade name for pirfenidone is Esbriet.
FORBES: Magazine Article